Cardio-Oncology and Heart Failure: AL Amyloidosis for the Heart Failure Clinician: a Supplement to the Scientific Statement from the Heart Failure Society of America
Authors:
- Michelle Weisfelner BloomMBMichelle Weisfelner Bloom
- Jo E. RodgersJRJo E. Rodgers
- Michelle M. KittlesonMKMichelle M. Kittleson
- 15 October 2024
- journal article
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 31 (2) , 456-463
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Safety and Efficacy of SGLT2 Inhibitors for Amyloid Light-Chain CardiomyopathyJournal of Cardiac Failure, 2024
- SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid CardiomyopathyJACC, 2024
- 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac AmyloidosisJACC, 2023
- Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatmentAmerican Journal of Hematology, 2022
- Expert consensus on the monitoring of transthyretin amyloid cardiomyopathyEuropean Journal of Heart Failure, 2021
- Safety and Tolerability of Neurohormonal Antagonism in Cardiac AmyloidosisEuropean Journal of Internal Medicine, 2020
- Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected AmyloidosisJACC, 2020
- AL Amyloidosis for the Cardiologist and OncologistJACC: Cardiooncology, 2019
- Transthyretin Amyloid CardiomyopathyJACC, 2019
- Direct Current Cardioversion of Atrial Arrhythmias in Adults With Cardiac AmyloidosisJACC, 2019